Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer.

In contrast, in patients with EGFR-WT (including KRAS mutations, ALK fusion, and none of three mutations named as triple-negative type), the PFS of high-RS patients tended to be shorter although it failed to reach statistical significance ( P > 0.05) potentially due to the small sample size ( Figures 4A, B ).

also in 6,035 other papers